dd-1

CDD-1102 HCl is a novel BRDT-BD4 BRD2-BD1302 selective inhibitor that shows non-hormonal contraceptive potential in ex vivo experiments.

EIDD-1931 (Beta-d-N4-hydroxycytidine) is a ribonucleoside analog with antiviral activity that inhibits the replication of severe acute respiratory syndrome coronavirus [SARS-CoV] in Vero 76 cells, Middle East respiratory syndrome coronavirus [MERS-CoV] in Calu-3 2B4 cells, and SARS-CoV-2 in Vero cells (IC50s = 0.1, 0.15, and 0.3 μM, respectively).

CDD-1431 is a highly selective BMPR2 kinase inhibitor with a Kiapp of 20.6 nM. It inhibits BRE reporter gene activity, exhibiting an IC50 of 4.87 μM. BMPs regulate cellular processes across various tissue types such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

CDD-1281 is a potent and highly selective inhibitor of the BMPR2 kinase, with an IC50 value of 1.2 nM. It effectively blocks BMP-mediated gene expression.

CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.

ADD 17014 is an anticonvulsant agent. It has a broad and unique spectrum of anticonvulsant activity.

EIDD-1619 is a novel water-soluble analog of progesterone.

DD-161515 is a VR1 antagonist.

CDD-1819, a non-covalent and non-peptide compound, serves as a potent SARS-CoV-2 Mpro inhibitor, exhibiting a K i value of 5 nM. It also effectively inhibits the Mpro variants ΔP168, A173V, and ΔP168 A173V [1].

CDD-1733 is a potent, non-covalent, and non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro) with an inhibition constant (K i) of 12 nM. It effectively inhibits Mpro variants including ΔP168, A173V, and the combined ΔP168 A173V [1].

CDD-1845, a non-covalent, non-peptide inhibitor, exhibits potent inhibition of SARS-CoV-2 M^pro with a K_i value of 3 nM. Additionally, CDD-1845 is effective against M^pro variants ΔP168, A173V, and the combined ΔP168 A173V variant [1].

CDD-1653 is a potent BMPR2 selective inhibitor with an IC50 of 2.8 nM. It acts by inhibiting the binding of ATP to the kinase domain of BMPR2, thereby affecting the phosphorylation of the transcription factors SMAD1 5 8, which play a crucial role in the BMP signaling pathway. CDD-1653 is utilized in research related to diseases associated with the BMP signaling pathway.

DD1 (HUN85111) is a proteasome inhibitor that induces human myeloid tumor-selective apoptosis.

Lodenosine is an inhibitor of RNA-directed DNA polymerase, and potentially for the treatment of HIV.

Propanocaine, classified as a benzyl alcohol derivative, exhibits properties of a local anesthetic.

DD-03-156 is a potent and selective degrader of CDK17 and LIMK2 . The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17 [1] .